Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Intensive Urate Lowering Therapy (ULT) With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout Using Surrogate Markers: a Randomized, Controlled Trial

NCT02500641 is registered in ClinicalTrials.gov with Menarini International Operations Luxembourg SA as lead sponsor.

NCT NCT02500641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02500641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Intensive Urate Lowering Therapy (ULT) With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout Using Surrogate Markers: a Randomized, Controlled Trial
Lead sponsor
Menarini International Operations Luxembourg SA
Phase
Phase 4
Overall status
Completed
Start date
August 17, 2015
Completion date
May 10, 2017
Enrollment
196 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

gout